Navigation Links
Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Date:7/25/2008

of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborator, in connection with the development and commercialization of Genaera's IL-9 antibody program; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any
'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Established and new medical technology service ... penetrate the growing Eastern European medical devices market. ... team and regional/local offices, reducing the costs incurred ... crucial advantage as medical technology service providers are ... New analysis from Frost & Sullivan, Medical Technologies ...
(Date:9/30/2014)... , Sept. 30, 2014 CytRx ... research and development company specializing in oncology, today ... clinical trial evaluating aldoxorubicin compared to topotecan in ... who have relapsed or were refractory to prior ... widely-used chemotherapeutic agent, doxorubicin. CytRx has received Orphan ...
(Date:9/29/2014)...  Repeated exposure to broad-spectrum antibiotics in the first ... obesity, say researchers from The Children,s Hospital of ... on data from electronic health records from the extensive ... that children with four or more exposures to broad ... be at risk for obesity. The study, published online ...
Breaking Medicine Technology:Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 2Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... reach USD 8,020.1 million by 2020, according to ... Growing demand for personalized medicine and theranostics, and ... are expected to be key factors driving market ... growing global base of geriatric population and chronic ...
(Date:9/30/2014)... During this online virtual event, ... health including achieving hormonal balance, relieving menopause symptoms, ... , The details of the ... 6-9, 2014, Location: Online Event, Registration: Complimentary , ... , Monday, October 6th, Steven F. Hotze, M.D., ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... Washington, DC (PRWEB) September ... **MEDIA ADVISORY** , ... Contact:    Anne Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Give Hope® Celebration , ... , Address:    The Army and ...
(Date:9/30/2014)... York (PRWEB) September 30, 2014 ... of Hudson Allergy , will discuss how restaurants ... allergies and other special dietary restrictions at the ... & Food Service Professionals, October 21 in New York ... this incredibly important topic to such an engaged industry ...
Breaking Medicine News(10 mins):Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... how we put the brakes on a racing heartbeat. ... Chicago explain in the May 11 issue of Circulation Research ... the rapid beating of the heart's "fight-or-flight" reaction to adrenaline. ... is responsible for setting the pace of the beating heart, ...
... The central government is aiming for 100 percent registration of ... Death Act 1969 that would simplify the process, an ... serious issue as this helps in maintaining a record for ... the birth registration record is 64 percent as some of ...
... 100 percent registration of births by 2010 by amending the ... simplify the process, an official said Friday. ,'Registration ... maintaining a record for a person for his or her ... percent as some of the states have still not implemented ...
... a single sphere in the US they would like to ... is the cooked chickens market. ,The U.S. ... to familiarize the U.S. market with its cooked chickens." ... about such common practices among Chinese farmers, like flooding crops ...
... of motor disorders: stiffness, slowness, tremors, difficulties walking and ... other symptoms with narcolepsy, a sleep disorder characterized by ... and general sleep disorder. ,Now a team ... why the two disorders share something in common: ...
... receiver Robert Sillen, hired to improve healthcare for state ... his jurisdiction. ,According to Sillen the 50-page ... and protect California communities from diseases carried by inmates ... says, taxpayers will get more for their dollar from ...
Cached Medicine News:Health News:Slowing the Racing Heart 2Health News:Government to Amend Birth Registration Act 2Health News:Government to Amend Birth Registration Act 2Health News:China Eyeing US Cooked Chickens Market 2Health News:UCLA Researchers Discover Link Between Parkinsons and Narcolepsy 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: